<DOC>
	<DOCNO>NCT00508859</DOCNO>
	<brief_summary>This study examine benefit continued treatment antidepressant medication , sertraline , adolescent depression improve sertraline acutely . We hypothesize adolescent remain sertraline long term less likely recurrence depression compare placebo .</brief_summary>
	<brief_title>Maintenance Study Adolescent Depression</brief_title>
	<detailed_description>This study design randomize control trial maintenance treatment sertraline adolescent age 13-19 depression . Subjects Subjects age 13-19 recruited , 18 month , mood disorder clinics 3 tertiary care centre across Canada . Informed consent obtain eligible interested subject parent ( subject &lt; 16 year age ) . Subjects eligible entry study diagnosis Major Depression determine clinical interview Schedule Affective Disorders Schizophrenia Children ( K-SAD-PL ) score &gt; 16 first 17 item 29-item Hamilton Rating Scale Depression ( HAM-D ) . Subjects exclude past current hypomanic manic episode , current psychotic symptom , substance dependence last 3 month , significant medical condition would contra-indicate use antidepressant untreated may require medical attention , pregnancy , past treatment sertraline major depression . Interventions Procedures There 3 phase study : 1 ) 12-week acute phase , 2 ) 24-week continuation phase , 3 ) 52-week maintenance phase . In general , subject assess every 2 week throughout study except first 4 week maintenance phase see contacted weekly . In continuation maintenance phase , every 2nd visit conduct person assessment could conduct either telephone person . Initial sertraline dose acute phase either 25 mg 50 mg daily increase 25 50 mg every 2 week treat clinician ' discretion , maximum 200 mg daily . For responder enter continuation phase re-emergence symptom without relapse , dose increase sertraline permit every 2 week maximum dose 200 mg daily first 8 week continuation phase . If subject experience side effect , one dose decrease permit first 8 week continuation phase . Subjects maintain response continuation randomize continue sertraline take placebo . In placebo group , sertraline taper 25 % initial dose every week first 4 week maintenance phase . During maintenance phase , treatment change permit . Subjects respond acute phase treatment , define 2 consecutive HAMD &lt; 9 great 50 % reduction HAM-D score within 12 week , offer entry continuation phase . Inter-rater reliability HAM-D test annually site project coordinator research assistant . Further training evaluation implement inter-rater reliability 0.8 great . Relapse continuation recurrence maintenance phase determine accord clinical judgement treat physician major depression recur intervention beyond permit study protocol require . Adverse event collect use Common Adverse Side Effects Scale . The scale administer every 2 week acute phase every 4 week continuation maintenance phase . Blinding Randomization Randomization conduct study pharmacist use computer generate randomization schedule . Subjects , clinician research staff remain blinded treatment randomization phase . All statistical analysis conduct independent statistician blind patient allocation .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<criteria>Age 1319 Diagnosis Major Depression History mania/hypomania Current psychotic symptom Substance dependence Medical condition ( contraindication sertraline ) Pregnancy Past treatment sertraline</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>depression</keyword>
	<keyword>adolescent</keyword>
	<keyword>maintenance treatment</keyword>
	<keyword>antidepressant</keyword>
</DOC>